Financial Gravity Companies Inc. Takes Position in Icon Plc (ICLR)
Financial Gravity Companies Inc. acquired a new position in shares of Icon Plc (NASDAQ:ICLR) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 1,314 shares of the medical research company’s stock, valued at approximately $144,000.
A number of other large investors have also recently bought and sold shares of ICLR. Principal Financial Group Inc. increased its stake in Icon by 71.5% during the 3rd quarter. Principal Financial Group Inc. now owns 768,471 shares of the medical research company’s stock worth $87,513,000 after buying an additional 320,356 shares in the last quarter. WCM Investment Management CA increased its stake in Icon by 5.8% during the 4th quarter. WCM Investment Management CA now owns 4,281,211 shares of the medical research company’s stock worth $480,138,000 after buying an additional 233,990 shares in the last quarter. Ameriprise Financial Inc. increased its stake in Icon by 530.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 248,202 shares of the medical research company’s stock worth $28,265,000 after buying an additional 208,816 shares in the last quarter. Westfield Capital Management Co. LP increased its stake in Icon by 12.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 869,018 shares of the medical research company’s stock worth $98,964,000 after buying an additional 94,345 shares in the last quarter. Finally, Atlantic Trust Group LLC purchased a new stake in Icon during the 3rd quarter worth approximately $9,515,000. Institutional investors own 89.18% of the company’s stock.
Several research firms have commented on ICLR. Credit Suisse Group upgraded Icon to a “buy” rating and set a $131.00 price objective for the company in a research note on Friday, February 16th. Mizuho reiterated a “neutral” rating and set a $114.00 price objective (up from $109.00) on shares of Icon in a research note on Thursday, February 15th. ValuEngine upgraded Icon from a “hold” rating to a “buy” rating in a research report on Tuesday, February 13th. BidaskClub upgraded Icon from a “strong sell” rating to a “sell” rating in a research report on Friday, February 9th. Finally, SunTrust Banks restated a “buy” rating and issued a $133.00 price target on shares of Icon in a research report on Monday, January 22nd. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $126.00.
Icon (NASDAQ:ICLR) last posted its quarterly earnings results on Thursday, February 15th. The medical research company reported $1.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.41 by $0.02. The business had revenue of $455.10 million during the quarter, compared to analyst estimates of $455.66 million. Icon had a return on equity of 28.60% and a net margin of 16.01%. The business’s revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the business earned $1.33 earnings per share. sell-side analysts predict that Icon Plc will post 6.02 EPS for the current fiscal year.
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.